MindBio Therapeutics（MBQI.F）株式概要マインドバイオ・セラピューティクス社（MindBio Therapeutics Corp.）は、その子会社とともに、オーストラレーシアにおいて、様々な精神疾患の潜在的治療薬としてのサイケデリック物質の研究、開発、試験に従事している。 詳細MBQI.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( A$0 )意味のある時価総額がありません ( $4M )すべてのリスクチェックを見るMBQI.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.58該当なし内在価値ディスカウントEst. Revenue$PastFuture-6m197k2016201920222025202620282031Revenue AU$1.0Earnings AU$0.2AdvancedSet Fair ValueView all narrativesMindBio Therapeutics Corp. 競合他社SoligenixSymbol: NasdaqCM:SNGXMarket cap: US$4.0mRevelation BiosciencesSymbol: NasdaqCM:REVBMarket cap: US$4.0mVivoSim LabsSymbol: NasdaqCM:VIVSMarket cap: US$3.9mDecoy TherapeuticsSymbol: NasdaqCM:DCOYMarket cap: US$3.9m価格と性能株価の高値、安値、推移の概要MindBio Therapeutics過去の株価現在の株価CA$0.5852週高値CA$2.4452週安値CA$0.28ベータ-1.391ヶ月の変化45.00%3ヶ月変化-16.96%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-37.73%最新ニュースお知らせ • May 11MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AIMindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • May 07MindBio Therapeutics Corp. Develops Cross-Language AI Speech Analytics Capability for Intoxication DetectionMindBio Therapeutics Corp. announced the Company has developed a cross-language speech model for the detection of drug and alcohol intoxication. The language agnostic model is a game changer for the non-invasive detection of a range of neurologically active substances from a voice recording across cultures and languages. The technology being developed by MindBio is a game changer for intoxication detection where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming, physically invasive and expensive. MindBio has developed an AI model currently being integrated into an Edge AI touchscreen kiosk, that can detect a range of neurologically active substances that impair cognition and performance. The technology is a game changer for the scalable detection of substance use in workplace health, safety and law enforcement. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • May 01MindBio Therapeutics Corp Files Patent Applications For Voice and AI Drug and Alcohol Intoxication Detection TechnologyMindBio Therapeutics Corp. had filed patent applications for its technology that uses voice and AI to detect intoxication. The technology developed by MindBio is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and in law enforcement where high-volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. In a world first, MindBio has developed an AI model that powers its Edge AI Intoxication Detection Kiosks, using over 50 million data points to predict drug and alcohol intoxication with remarkable reliability and accuracy, just by using the human voice. The Company’s novel discoveries that have led to its patent application filings, allow it to use its prediction technology to detect a range of substances that effect the central nervous system and human cognition and performance. The Company also announced that it is on track for the delivery of its hardware and software solution, an Edge AI touchscreen kiosk for commercial testing, specifically for the mining and aviation industries by the end of Second Quarter, 2026. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • Apr 14MindBio Therapeutics Corp. Deploys New Technology Intox Collect And Expands CNS Drug Detection Capabilities With Voice And Facial RecognitionMindBio Therapeutics Corp. had completed the development of new technology Intox Collect which has enabled the Company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed. Intox Collect is a novel software which has enhanced the Company’s data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system. In a world first, MindBio has developed an AI model that uses over 50 million data points, (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the Company’s new Intox Collect™ software allows the company to expand its prediction technology to a range of substances that effect the central nervous system, which when consumed impair cognition and human performance. The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and where high volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. The Company recently announced that a prototype design for its new Edge AI Hardware-Software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in the Second Quarter, 2026.お知らせ • Apr 03MindBio Therapeutics Corp. announced that it has received CAD 1.437829 million in fundingOn April 1, 2026, MindBio Therapeutics Corp closed the transaction. The company announced that it has issued 2,396,381 units at a price of CAD 0.60 per Unit for gross proceeds of 1,437,828.87. In connection with completion of the Offering, the Company paid aggregate cash fees of CAD 70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of CAD 0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals.お知らせ • Feb 19MindBio Therapeutics Corp. announced that it expects to receive CAD 0.65 million in fundingMindBio Therapeutics Corp non-brokered private placement to issue 1,083,333 units at an issue price of CAD 0.60 for the proceeds of CAD 649,999.8 on February 19, 2026. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of CAD 0.80 for a period of 36 months following closing of the offering. In connection with completion of the offering, the company will pay finders' fees to eligible third parties which have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws. Completion of the offering remains subject to final board and regulatory approvals.最新情報をもっと見るRecent updatesお知らせ • May 11MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AIMindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • May 07MindBio Therapeutics Corp. Develops Cross-Language AI Speech Analytics Capability for Intoxication DetectionMindBio Therapeutics Corp. announced the Company has developed a cross-language speech model for the detection of drug and alcohol intoxication. The language agnostic model is a game changer for the non-invasive detection of a range of neurologically active substances from a voice recording across cultures and languages. The technology being developed by MindBio is a game changer for intoxication detection where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming, physically invasive and expensive. MindBio has developed an AI model currently being integrated into an Edge AI touchscreen kiosk, that can detect a range of neurologically active substances that impair cognition and performance. The technology is a game changer for the scalable detection of substance use in workplace health, safety and law enforcement. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • May 01MindBio Therapeutics Corp Files Patent Applications For Voice and AI Drug and Alcohol Intoxication Detection TechnologyMindBio Therapeutics Corp. had filed patent applications for its technology that uses voice and AI to detect intoxication. The technology developed by MindBio is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and in law enforcement where high-volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. In a world first, MindBio has developed an AI model that powers its Edge AI Intoxication Detection Kiosks, using over 50 million data points to predict drug and alcohol intoxication with remarkable reliability and accuracy, just by using the human voice. The Company’s novel discoveries that have led to its patent application filings, allow it to use its prediction technology to detect a range of substances that effect the central nervous system and human cognition and performance. The Company also announced that it is on track for the delivery of its hardware and software solution, an Edge AI touchscreen kiosk for commercial testing, specifically for the mining and aviation industries by the end of Second Quarter, 2026. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • Apr 14MindBio Therapeutics Corp. Deploys New Technology Intox Collect And Expands CNS Drug Detection Capabilities With Voice And Facial RecognitionMindBio Therapeutics Corp. had completed the development of new technology Intox Collect which has enabled the Company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed. Intox Collect is a novel software which has enhanced the Company’s data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system. In a world first, MindBio has developed an AI model that uses over 50 million data points, (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the Company’s new Intox Collect™ software allows the company to expand its prediction technology to a range of substances that effect the central nervous system, which when consumed impair cognition and human performance. The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and where high volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. The Company recently announced that a prototype design for its new Edge AI Hardware-Software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in the Second Quarter, 2026.お知らせ • Apr 03MindBio Therapeutics Corp. announced that it has received CAD 1.437829 million in fundingOn April 1, 2026, MindBio Therapeutics Corp closed the transaction. The company announced that it has issued 2,396,381 units at a price of CAD 0.60 per Unit for gross proceeds of 1,437,828.87. In connection with completion of the Offering, the Company paid aggregate cash fees of CAD 70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of CAD 0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals.お知らせ • Feb 19MindBio Therapeutics Corp. announced that it expects to receive CAD 0.65 million in fundingMindBio Therapeutics Corp non-brokered private placement to issue 1,083,333 units at an issue price of CAD 0.60 for the proceeds of CAD 649,999.8 on February 19, 2026. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of CAD 0.80 for a period of 36 months following closing of the offering. In connection with completion of the offering, the company will pay finders' fees to eligible third parties which have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws. Completion of the offering remains subject to final board and regulatory approvals.株主還元MBQI.FUS BiotechsUS 市場7D-14.7%3.1%1.2%1Yn/a34.6%28.7%株主還元を見る業界別リターン: MBQI.FがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: MBQI.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is MBQI.F's price volatile compared to industry and market?MBQI.F volatilityMBQI.F Average Weekly Movementn/aBiotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間のMBQI.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2021n/aJustin Hankawww.mindbiotherapeutics.comマインドバイオ・セラピューティクス社（MindBio Therapeutics Corp.）は、その子会社とともに、オーストラレーシアにおいて、さまざまな精神疾患の潜在的治療薬としてのサイケデリック物質の研究、開発、試験に従事している。同社の主要医薬品候補はMB22001で、リゼルグ酸ジエチルアミドの一種である。同社はまた、サイケデリック医薬品を服用するメンタルヘルス患者の生体データを収集するウェアラブルデバイスを開発し、うつ病、不安神経症、PTSD、慢性疼痛などの衰弱した健康状態に対する新規かつ臨床的に証明された治療法を開発するための基礎となる研究に投資している。マインドバイオ・セラピューティクス社は2021年に設立され、カナダのバンクーバーに本社を置いている。もっと見るMindBio Therapeutics Corp. 基礎のまとめMindBio Therapeutics の収益と売上を時価総額と比較するとどうか。MBQI.F 基礎統計学時価総額US$4.06m収益（TTM）-US$4.31m売上高(TTM)n/a0.0xP/Sレシオ-1.0xPER（株価収益率MBQI.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MBQI.F 損益計算書（TTM）収益AU$0売上原価AU$0売上総利益AU$0その他の費用AU$6.01m収益-AU$6.01m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.82グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-110.5%MBQI.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 03:03終値2026/05/26 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MindBio Therapeutics Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 11MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AIMindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • May 07MindBio Therapeutics Corp. Develops Cross-Language AI Speech Analytics Capability for Intoxication DetectionMindBio Therapeutics Corp. announced the Company has developed a cross-language speech model for the detection of drug and alcohol intoxication. The language agnostic model is a game changer for the non-invasive detection of a range of neurologically active substances from a voice recording across cultures and languages. The technology being developed by MindBio is a game changer for intoxication detection where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming, physically invasive and expensive. MindBio has developed an AI model currently being integrated into an Edge AI touchscreen kiosk, that can detect a range of neurologically active substances that impair cognition and performance. The technology is a game changer for the scalable detection of substance use in workplace health, safety and law enforcement. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • May 01MindBio Therapeutics Corp Files Patent Applications For Voice and AI Drug and Alcohol Intoxication Detection TechnologyMindBio Therapeutics Corp. had filed patent applications for its technology that uses voice and AI to detect intoxication. The technology developed by MindBio is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and in law enforcement where high-volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. In a world first, MindBio has developed an AI model that powers its Edge AI Intoxication Detection Kiosks, using over 50 million data points to predict drug and alcohol intoxication with remarkable reliability and accuracy, just by using the human voice. The Company’s novel discoveries that have led to its patent application filings, allow it to use its prediction technology to detect a range of substances that effect the central nervous system and human cognition and performance. The Company also announced that it is on track for the delivery of its hardware and software solution, an Edge AI touchscreen kiosk for commercial testing, specifically for the mining and aviation industries by the end of Second Quarter, 2026. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • Apr 14MindBio Therapeutics Corp. Deploys New Technology Intox Collect And Expands CNS Drug Detection Capabilities With Voice And Facial RecognitionMindBio Therapeutics Corp. had completed the development of new technology Intox Collect which has enabled the Company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed. Intox Collect is a novel software which has enhanced the Company’s data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system. In a world first, MindBio has developed an AI model that uses over 50 million data points, (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the Company’s new Intox Collect™ software allows the company to expand its prediction technology to a range of substances that effect the central nervous system, which when consumed impair cognition and human performance. The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and where high volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. The Company recently announced that a prototype design for its new Edge AI Hardware-Software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in the Second Quarter, 2026.
お知らせ • Apr 03MindBio Therapeutics Corp. announced that it has received CAD 1.437829 million in fundingOn April 1, 2026, MindBio Therapeutics Corp closed the transaction. The company announced that it has issued 2,396,381 units at a price of CAD 0.60 per Unit for gross proceeds of 1,437,828.87. In connection with completion of the Offering, the Company paid aggregate cash fees of CAD 70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of CAD 0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals.
お知らせ • Feb 19MindBio Therapeutics Corp. announced that it expects to receive CAD 0.65 million in fundingMindBio Therapeutics Corp non-brokered private placement to issue 1,083,333 units at an issue price of CAD 0.60 for the proceeds of CAD 649,999.8 on February 19, 2026. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of CAD 0.80 for a period of 36 months following closing of the offering. In connection with completion of the offering, the company will pay finders' fees to eligible third parties which have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws. Completion of the offering remains subject to final board and regulatory approvals.
お知らせ • May 11MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AIMindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • May 07MindBio Therapeutics Corp. Develops Cross-Language AI Speech Analytics Capability for Intoxication DetectionMindBio Therapeutics Corp. announced the Company has developed a cross-language speech model for the detection of drug and alcohol intoxication. The language agnostic model is a game changer for the non-invasive detection of a range of neurologically active substances from a voice recording across cultures and languages. The technology being developed by MindBio is a game changer for intoxication detection where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming, physically invasive and expensive. MindBio has developed an AI model currently being integrated into an Edge AI touchscreen kiosk, that can detect a range of neurologically active substances that impair cognition and performance. The technology is a game changer for the scalable detection of substance use in workplace health, safety and law enforcement. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • May 01MindBio Therapeutics Corp Files Patent Applications For Voice and AI Drug and Alcohol Intoxication Detection TechnologyMindBio Therapeutics Corp. had filed patent applications for its technology that uses voice and AI to detect intoxication. The technology developed by MindBio is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and in law enforcement where high-volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. In a world first, MindBio has developed an AI model that powers its Edge AI Intoxication Detection Kiosks, using over 50 million data points to predict drug and alcohol intoxication with remarkable reliability and accuracy, just by using the human voice. The Company’s novel discoveries that have led to its patent application filings, allow it to use its prediction technology to detect a range of substances that effect the central nervous system and human cognition and performance. The Company also announced that it is on track for the delivery of its hardware and software solution, an Edge AI touchscreen kiosk for commercial testing, specifically for the mining and aviation industries by the end of Second Quarter, 2026. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • Apr 14MindBio Therapeutics Corp. Deploys New Technology Intox Collect And Expands CNS Drug Detection Capabilities With Voice And Facial RecognitionMindBio Therapeutics Corp. had completed the development of new technology Intox Collect which has enabled the Company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed. Intox Collect is a novel software which has enhanced the Company’s data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system. In a world first, MindBio has developed an AI model that uses over 50 million data points, (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the Company’s new Intox Collect™ software allows the company to expand its prediction technology to a range of substances that effect the central nervous system, which when consumed impair cognition and human performance. The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and where high volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. The Company recently announced that a prototype design for its new Edge AI Hardware-Software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in the Second Quarter, 2026.
お知らせ • Apr 03MindBio Therapeutics Corp. announced that it has received CAD 1.437829 million in fundingOn April 1, 2026, MindBio Therapeutics Corp closed the transaction. The company announced that it has issued 2,396,381 units at a price of CAD 0.60 per Unit for gross proceeds of 1,437,828.87. In connection with completion of the Offering, the Company paid aggregate cash fees of CAD 70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of CAD 0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals.
お知らせ • Feb 19MindBio Therapeutics Corp. announced that it expects to receive CAD 0.65 million in fundingMindBio Therapeutics Corp non-brokered private placement to issue 1,083,333 units at an issue price of CAD 0.60 for the proceeds of CAD 649,999.8 on February 19, 2026. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of CAD 0.80 for a period of 36 months following closing of the offering. In connection with completion of the offering, the company will pay finders' fees to eligible third parties which have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws. Completion of the offering remains subject to final board and regulatory approvals.
